Filtered By:
Therapy: Endocrine Therapy

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 38 results found since Jan 2013.

Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13
Conclusions: We show that the PKA-anchoring protein AKAP13 is essential for the phosphorylation of ERαS305, which leads to tamoxifen resistance both in cell lines and tamoxifen-treated breast cancer patients.
Source: BMC Cancer - August 14, 2015 Category: Cancer & Oncology Authors: Cristiane Bentin ToaldoXanthippi AlexiKarin BeelenMarleen KokMichael HauptmannMaurice JansenEls BernsJacques NeefjesSabine LinnRob MichalidesWilbert Zwart Source Type: research

Abstract 2435: FGFR1 is associated with resistance to interaction with estrogen receptor (ER) {alpha} endocrine therapy in ER+/FGFR1-amplified breast cancer
Conclusions: These data suggest FGFR1 binds ER and regulates ligand-independent ER transcriptional activity. This role depends on the FGFR1 kinase activity and may involve its association with cyclin D1. These interactions may explain the endocrine resistance reported in ER+/FGFR1 amplified breast cancers and suggest these tumors should be treated with a combination of antiestrogen and FGFR inhibitors.Citation Format: Luigi Formisano, Christian D. Young, Neil Bhola, Jennifer M. Giltnane, Monica V. Estrada, Carlos L. Arteaga. FGFR1 is associated with resistance to interaction with estrogen receptor (ER) α endocrine therapy...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Formisano, L., Young, C. D., Bhola, N., Giltnane, J. M., Estrada, M. V., Arteaga, C. L. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research

Abstract P3-04-05: Invasive lobular carcinoma cell lines utilize WNT4 signaling to mediate estrogen-induced growth
Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer representing 10-15% of newly diagnosed breast tumors. Over 90% of ILC are ER-positive, however, endocrine response and estrogen signaling are not well described in ILC. Retrospective analyses suggest that ILC patients treated with endocrine therapy have poorer outcomes than similar invasive ductal carcinoma (IDC) patients, and that ILC patients may not benefit from adjuvant tamoxifen. Additionally, we recently identified ILC-specific ER-target genes and de novo tamoxifen resistance driven by ER in ILC model systems. Based on these observations, we ...
Source: Cancer Research - April 30, 2015 Category: Cancer & Oncology Authors: Sikora, M. J., Bahreini, A., Alexander, C. M., Oesterreich, S. Tags: Poster Session Abstracts Source Type: research

Abstract 4227: The ribonucleotide reductase inhibitor Didox reverses tamoxifen resistance in breast cancer cells
In this study, we report that the inhibition of RRM2 by the small molecule inhibitor of ribonucleotide reductase activity Didox (3, 4-dihydroxybenzohydroxamic acid), significantly reduced tamoxifen induced cell proliferation in AKT overexpressing cells and tamoxifen resistant tumors generated by these cells. As well, Didox in combination with tamoxifen also inhibited cell proliferation in acquired tamoxifen resistant breast cancer cell lines. Employing comprehensive cell culture and in vivo models, we demonstrate that combining tamoxifen with Didox may reverse tamoxifen resistance in AKT expressing breast cancer cells. Cit...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Shah, K. N., Elford, H. L., Faridi, J. S. Tags: Molecular and Cellular Biology Source Type: research

Abstract 2739: Specific interaction of human MGMT with ER-{alpha} in breast cancer cells: Co-degradation of MGMT and ER- {alpha} proteins by either fulvestrant or O6-benzylguanine and its therapeutic significance
This study investigated whether i) MGMT is modulated by endocrine therapies, ii) MGMT interacts with ER-signaling components and iii) if such findings are exploitable for improved breast cancer treatment. The ER-α positive cell lines MCF-7, T47D and ER- α negative MDAMB 468 cells, all MGMT-proficient, were treated with Fulvestrant (Faslodex, ICI 182, 780) or O6-benzylguanine (BG) in various experiments. Fulvestrant is a pure antiestrogen that binds to ER without eliciting any transcriptional effects, but leads to the receptor degradation through the ubiquitin-proteasome (ub-P) pathway. BG is a specific pseudosubstrate fo...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Srivenugopal, K. S., Paranjpe, A. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 4755: Estrogen receptor mediates novel mechanisms of estrogen-induced growth and tamoxifen resistance in invasive lobular carcinoma
Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer representing ∼10% of newly diagnosed breast tumors. Over 90% of ILC cases are ER-positive, however, endocrine response and estrogen signaling are not well described in ILC. Retrospective analyses suggest that ILC patients treated with endocrine therapy have poorer outcomes than invasive ductal carcinoma (IDC) patients with similar biomarkers, and that ILC patients may not benefit from adjuvant tamoxifen. Additionally, we have recently identified ILC-specific ER-target genes and de novo tamoxifen resistance driven by ER in ILC model systems. Based...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Sikora, M. J., Bahreini, A., Oesterreich, S. Tags: Endocrinology Source Type: research

Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
Conclusions: Our study shows that TNBC cells have profound metabolic alterations characterized by decreased mitochondrial respiration and increased glycolysis. Due to their impaired mitochondrial function, TNBC cells are highly sensitive to glycolytic inhibition, suggesting that such metabolic intervention may be an effective therapeutic strategy for this subtype of breast cancer cells.
Source: Breast Cancer Research - September 11, 2014 Category: Cancer & Oncology Authors: Hélène PelicanoWan ZhangJinyun LiuNaima HammoudiJiale DaiRui-hua XuLajos PusztaiPeng Huang Source Type: research

p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptility to 3-bromopyruvate in ERα+ breast cancer MCF-7 cells.
Conclusions.- a) ERα(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; b) targeting the pyruvate pathway may improve response to endocrine therapy in ERα(+) breast cancer with p53 dysfunction. PMID: 24486524 [PubMed - as supplied by publisher]
Source: Biochemical Pharmacology - January 28, 2014 Category: Drugs & Pharmacology Authors: Rieber M, Strasberg-Rieber M Tags: Biochem Pharmacol Source Type: research